This study was conducted to investigate any potential reaction between irbesartan and hydrochlorothiazide.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
18
Pharmaceutics Department, Faculty of Pharmacy, Damanhour University
Damanhur, Egypt
Blood pressure (systolic/diastolic)
Time frame: participants will be followed for the duration of hospital stay, an expected average of 5 weeks
pharmacokinetic parameter such as the Cmax of irbesartan and hydrochlorothiazide
Time frame: After collection of all blood samples, an expected average of 4 weeks
Heart rate
Time frame: participants will be followed for the duration of hospital stay, an expected average of 5 weeks
pharmacokinetic parameter such as the AUC of irbesartan and hydrochlorothiazide
Time frame: After collection of all blood samples, an expected average of 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.